Edgewise reports Q2, continues to advance drug in trials
BOULDER — Biopharmaceutical company Edgewise Therapeutics (NASDAQ: EWTX) reported Monday that its lead drug is advancing in clinical trials with topline data expected by the end of the year.
The drug, known as EDG-5506, is designed to treat rare muscle disorders.
Edgewise also reported its financial results for the second quarter of 2021. It lost $10.4 million, or 21 cents per share, a 160% increase from the $4 million it lost in the second quarter of 2020. In a statement, the company attributed that to increased research and development costs related to clinical drug trials, as well as higher administrative and labor…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
BOULDER — Even with the COVID-10 pandemic several years in the rearview mirror, it remains…
-
Columbine Health Systems will host Dementia Week, a series of free events devoted to educating…
-
Boulder Community Health this month became the first facility in Colorado to offer patients a…
-
Nextera Healthcare LLC and ImagineMD have combined to form a single direct-primary-care organization for employer…
